Recon: Amylyx withdraws ALS drug from US and Canada; Sanofi to settle 4,000 US Zantac cancer lawsuits

• Amylyx to pull ALS drug from market, cut 70% of staff (STAT)
• Experts applaud Amylyx for keeping its promise to withdraw ALS drug Relyvrio after trial failure (Endpoints) (STAT)
• For national security, the U.S. must maintain its biotech dominance (STAT)
• Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts (Reuters)
• Costco offering members access to weight-loss programs including medication (Reuters)
• Arbutus, Genevant gain an edge in COVID patent scrap with Moderna (Fierce Pharma)

• Mitsui and Rohto to buy $594 mln Chinese medicines company Eu Yan Sang (Reuters)
• UK watchdog says Theramex-Viatris deal raises competition concerns (Reuters)
• Drugmaker seeks approval for China's first biosimilar Ozempic (Reuters)
• Fresh Opportunity For Free Scientific Advice For High-Risk Devices From EU Expert Panels (MedTech Insight)
• Pharma Dubs EU HTA Proposal ‘Unworkable,’ But Patient Groups Support The Plan (Pink Sheet)
• EU Produces Guide On 'Challenges' To NASH Drug Development (Pink Sheet)
• China Implements Data Transfer Regulation, With Some Waivers (Pink Sheet)
• Japan's PMDA To Open First Global Office, In D.C. (Pink Sheet)

• How resurrecting extinct species might impact medicine (STAT)
• What ‘de-extinction’ of woolly mammoths can teach us: a Q&A with evolutionary biologist Beth Shapiro (STAT)
• Parkinson’s disease may be helped by GLP-1 drug, new study finds (STAT)
• Exclusive: Ex-Recursion team launches Leash Bio, challenging AI field with its bet on needing more data (Endpoints)
• eFFECTOR's lead lung cancer program falls through, stock crashes (Endpoints)
• Candel’s promising Ph2 data in pancreatic cancer; Microbiome biotech raises £27M (Endpoints)
• CureVac releases mixed interim Phase 2 data for seasonal flu vaccine (Endpoints)
• Teva, forging ahead with new strategy, inks biosimilar deal with Spain's mAbxience (Fierce Pharma)
• Apotex acquires specialty drugmaker Searchlight in expansion move (Fierce Pharma)

• DNA test that predicts opioid addiction should be pulled off the market, critics urge the FDA (STAT)
• Why a Medtronic exec thinks a convergence of med tech and consumer tech is coming (Endpoints)
• FTC asks Boston Scientific for more info on $3.7B Axonics deal (MedTech Dive)
• Teleflex catheterization kit recall linked to 10 injuries, 1 death (MedTech Dive)
• Eko wins FDA nod for AI to detect sign of heart failure using stethoscope (MedTech Dive)
• QuidelOrtho pulls FDA submission of 4-virus test (MedTech Dive)
• Thermo Fisher plots layoffs at California plasmid manufacturing site as demand swings (Fierce Pharma)

• Hospital care costs are out of control. Price caps can help (STAT)
• As cyberattacks on healthcare persist, can the FDA’s new device regs hold up? (MedTech Dive)
• Report Says VHA Needs Better Implant Tracking (MedTech Insight)
• FDA Tells Congress What It Wants, What it Really Really Wants (FDA Law Blog)
• Drug Cost-Sharing Limits Could Be Strengthened In Self-Insured, Large Group Plans In Upcoming Rule (Pink Sheet)
• Obesity Drugs Cost Concerns Not Yet Impacting HHS Risk Adjustment Models (Pink Sheet)